Neurocrine (NASDAQ: NBIX) director converts 3,318 RSUs to shares

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC director William H. Rastetter exercised restricted stock units into common shares. On May 21, 2026, he converted 3,318 Restricted Stock Units into 3,318 shares of common stock at a stated price of $0.00 per share, reflecting a compensation-related vesting event rather than a market purchase or sale.

After this transaction, Rastetter’s direct holdings increased to 43,678 common shares, which are held by the Rastetter Family Trust, where he has voting and investment power. The RSU award was granted on May 21, 2025 and was fully vested at the time of conversion, and no remaining derivative position is reported in this filing.

Insider Trade Summary

3,318 shares exercised/converted

Mixed 2 txns

Insider RASTETTER WILLIAM H

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	3,318	$0.00	--
Exercise	Common Stock	3,318	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct, null); Common Stock — 43,678 shares (Direct, null)

Footnotes (1)

1. 43,678 of the reported shares are held by the Rastetter Family Trust established September 2, 2010, of which the Reporting Person has voting and investment power. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested.

Key Figures

RSUs exercised: 3,318 units Shares received: 3,318 shares Post-transaction holdings: 43,678 shares +2 more

5 metrics

RSUs exercised 3,318 units Restricted Stock Units converted to common stock on May 21, 2026

Shares received 3,318 shares Common stock issued upon RSU conversion

Post-transaction holdings 43,678 shares Common stock beneficially held after May 21, 2026 transaction

RSU grant date May 21, 2025 Grant date of RSU award that is now fully vested

Exercise price $0.00 per share Stated price for RSU-to-common conversion

Key Terms

Restricted Stock Unit, derivative security, voting and investment power

3 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

voting and investment power financial

"of which the Reporting Person has voting and investment power."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RASTETTER WILLIAM H

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		M		3,318	A	$0	43,678(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0(2)	05/21/2026		M			3,318	(3)	(3)	Common Stock	3,318	$0	0	D

Explanation of Responses:

1. 43,678 of the reported shares are held by the Rastetter Family Trust established September 2, 2010, of which the Reporting Person has voting and investment power.

2. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

3. This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did William H. Rastetter report for NBIX?

William H. Rastetter reported exercising 3,318 Restricted Stock Units into 3,318 shares of Neurocrine Biosciences common stock. The transaction occurred on May 21, 2026, as a derivative exercise rather than an open-market buy or sell.

How many Neurocrine (NBIX) shares does William H. Rastetter hold after this Form 4?

After the reported transaction, William H. Rastetter beneficially holds 43,678 shares of Neurocrine Biosciences common stock. These shares are held by the Rastetter Family Trust, over which he has voting and investment power according to the filing’s footnote.

What happened to the 3,318 Restricted Stock Units reported in the NBIX Form 4?

The 3,318 Restricted Stock Units were converted into 3,318 shares of Neurocrine Biosciences common stock. Each RSU entitled the holder to receive one common share upon vesting, and the award referenced in the filing is fully vested.

Was the Neurocrine (NBIX) insider transaction a market purchase or sale?

The transaction was not a market purchase or sale; it was an exercise of a derivative security. Restricted Stock Units were converted into common shares at a stated price of $0.00 per share, reflecting equity compensation vesting rather than trading in the open market.

When was the Restricted Stock Unit award in the NBIX Form 4 originally granted?

The Restricted Stock Unit award referenced in the Form 4 was granted on May 21, 2025. By the time of the May 21, 2026 transaction, the award was fully vested, enabling conversion of all 3,318 RSUs into common shares.

Are there any remaining derivative securities for William H. Rastetter in this NBIX filing?

The filing does not show any remaining derivative securities for William H. Rastetter. The 3,318 Restricted Stock Units reported were fully converted into common shares, and the derivative summary in the data is empty after this exercise.